Comparative Pharmacology
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUINATIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPYRAMIDE PHOSPHATE versus QUINATIME.
DISOPYRAMIDE PHOSPHATE vs QUINATIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; inhibits cardiac sodium channels, prolongs action potential duration, increases effective refractory period, and reduces myocardial excitability and conduction velocity.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
100-200 mg orally every 6 hours; immediate-release: 100-200 mg every 6 hours; extended-release: 200-300 mg every 12 hours.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged to 15-25 hours in renal impairment (creatinine clearance <40 mL/min), requiring dose adjustment.
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Renal excretion of unchanged drug accounts for 40-60% of elimination; hepatic metabolism (N-dealkylation) accounts for 20-30%; approximately 10-15% excreted in feces via biliary elimination.
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Category D/X
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)